©The Author(s) 2022.
World J Clin Cases. Apr 16, 2022; 10(11): 3321-3333
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321
Table 2 Glypican-3 as molecule-target for hepatocellular carcinoma immunotherapy
| Group | Name | Species | Epitopes | Verifying/applying |
| Antibody | M18D04/19B11 | Mouse | N-terminal (aa: 25-358) | Basic studies |
| A1836A | Mouse | N- terminal | Basic studies | |
| GPC3-C02 | Mouse | C- terminal | Basic studies | |
| GC33 | Mouse | C-terminal (aa: 524-563) | Preclinical trial studies | |
| hGC33 | Human | C- terminal (aa: 524-563) | Clinical trial-II | |
| HS20 | Human | Heparan sulfate chain | Preclinical trial | |
| sGPC3 | Human | — | Preclinical trial | |
| Vaccines | GPC3298-306 | Mouse | 298-306 peptide | Clinical trial-II |
| GPC3144-152 | Mouse | 144-152 peptide | Clinical trial-II | |
| miRNA | miR-219-5p | Human | — | In vitro or in vivo studies |
| miR-520c-3p | Human | — | In vitro studies | |
| miR-1271 | Human | — | In vitro studies | |
| shRNA | GPC3 shRNA | Human | — | In vitro or in vivo studies |
| siRNA | GPC3 siRNA | Human | — | In vitro or in vivo studies |
- Citation: Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333
- URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3321.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3321